These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26247697)
61. The search for optimal response prediction in cancer leads to a personalized approach. Van Cutsem E; Ciardiello F Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283 [No Abstract] [Full Text] [Related]
62. The clonal relationships between pre-cancer and cancer revealed by ultra-deep sequencing. Wood HM; Conway C; Daly C; Chalkley R; Berri S; Senguven B; Stead L; Ross L; Egan P; Chengot P; Graham J; Sethi N; Ong TK; High A; MacLennan K; Rabbitts P J Pathol; 2015 Nov; 237(3):296-306. PubMed ID: 26096211 [TBL] [Abstract][Full Text] [Related]
63. Homing in on genomic instability as a therapeutic target in cancer. Bielski CM; Taylor BS Nat Commun; 2021 Jun; 12(1):3663. PubMed ID: 34135330 [TBL] [Abstract][Full Text] [Related]
64. From traditional molecular biology to network oncology. Ziogas DE; Katsios C; Roukos DH Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133 [No Abstract] [Full Text] [Related]
65. Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer. Kutzner A; Heese K Cancer Invest; 2016; 34(2):64-9. PubMed ID: 26854063 [TBL] [Abstract][Full Text] [Related]
66. The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors. Nandakumar V; Mills JR Clin Chem; 2019 Feb; 65(2):357. PubMed ID: 32100826 [No Abstract] [Full Text] [Related]
68. Current status of methods to assess cancer drug resistance. Lippert TH; Ruoff HJ; Volm M Int J Med Sci; 2011 Mar; 8(3):245-53. PubMed ID: 21487568 [TBL] [Abstract][Full Text] [Related]
69. Radiological assessment of tumour response to anti-cancer drugs: time to reappraise. Nygren P; Blomqvist L; Bergh J; Aström G Acta Oncol; 2008; 47(2):316-8. PubMed ID: 18210304 [No Abstract] [Full Text] [Related]
70. Editorial. Takata M Mutat Res; 2017 Oct; 803-805():42. PubMed ID: 28625404 [No Abstract] [Full Text] [Related]
71. Predicting and Understanding Cancer Response to Treatment. Callari M; Gandellini P; Skvortsova I; Span PN Dis Markers; 2018; 2018():6159214. PubMed ID: 30002742 [No Abstract] [Full Text] [Related]
72. Selected Articles from This Issue. Mol Cancer Ther; 2020 Jul; 19(7):1383. PubMed ID: 32616655 [No Abstract] [Full Text] [Related]
73. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. Yin A; Moes DJAR; van Hasselt JGC; Swen JJ; Guchelaar HJ CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):720-737. PubMed ID: 31250989 [TBL] [Abstract][Full Text] [Related]
74. Overcoming resistance to apoptosis in cancer therapy. Hersey P; Zhang XD; Mhaidat N Adv Exp Med Biol; 2008; 615():105-26. PubMed ID: 18437893 [No Abstract] [Full Text] [Related]
75. Evolution of acquired resistance to anti-cancer therapy. Foo J; Michor F J Theor Biol; 2014 Aug; 355():10-20. PubMed ID: 24681298 [TBL] [Abstract][Full Text] [Related]
77. Beyond bad luck: induced mutations and hallmarks of cancer. Kelly-Irving M; Delpierre C; Vineis P Lancet Oncol; 2017 Aug; 18(8):999-1000. PubMed ID: 28759371 [No Abstract] [Full Text] [Related]
78. Abstracts of the 9th World Congress on Advances in Oncology and the 7th International Symposium on Molecular Medicine. 14-16 October 2004, Hersonissos, Greece. Int J Mol Med; 2004; 14 Suppl 1():S5-87. PubMed ID: 15551488 [No Abstract] [Full Text] [Related]